Gubra at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
Gubra brings 4 presentations to ObesityWeek 2026 in National Harbor. Its posters present rodent models for obesity drug research, including sarcopenic obesity and dexamethasone-induced muscle atrophy for studying healthy weight loss. Others compare CagriSema with cagrilintide and semaglutide in obese rats and show orforglipron activating appetite-suppressing brain regions in a human GLP-1 receptor model.
| Organization | ObesityWeek 2026 Attendance |
|---|---|
Gubra Hørsholm, Denmark | |
Preclinical CRO and peptide drug-discovery company offering obesity and metabolic disease models and studies. | Poster Sat Nov 14 7:30pm–8:30pm Modeling Sarcopenic Obesity for Treatment of Healthy Weight Loss Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology Poster Sat Nov 14 7:30pm–8:30pm Superior Efficacy and Translatability of CagriSema Vs Cagrilintide and Semaglutide in DIO Rats Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology Poster Sun Nov 15 2:30pm–3:30pm Dexamethasone Induces Robust Skeletal Muscle Atrophy and Functional Decline in Mice Metabolism and integrative physiology Poster Sun Nov 15 2:30pm–3:30pm Orforglipron Induces Weight Loss and Activates Appetite-Suppressing Brain Regions in a HGLP-1R Model Interventional and clinical studies |
Find decision makers at Gubra
Tell us what you sell and we’ll find the people at Gubra most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction